Skip to main content

Table 2 Post-operation follow-up during the first 3 years by sociodemographic and clinical profile (N = 420)

From: Adherence to post-surgery follow-up assessment and its association with sociodemographic and disease characteristics in patients with breast cancer in Central China

Characteristic Frequency of follow-up in the first 3 years Total
N = 420
p*
0 n = 94 1 n = 50 2 n = 79 3 n = 197
Age(years)       < 0.01
  < 65 58 (61.7%) 39 (78.0%) 66 (83.5%) 189 (95.9%) 352 (83.8%)  
  > 65 36 (38.3%) 11 (22.0%) 13 (16.5%) 8 (4.1%) 68 (16.2%)  
Medical insurance coverage       < 0.01
 High (> 70%) 16 (17.0%) 10 (20.0%) 24 (30.4%) 77 (39.1%) 127 (30.2%)  
 Medium (50–70%) 50 (53.2%) 29 (58.0%) 35 (44.3%) 83 (42.1%) 197 (46.9%)  
 Low (< 50%) 28 (29.8%) 11 (22.0%) 20 (25.3%) 37 (18.8%) 96 (22.9%)  
Family history       0.89
 Negative 88 (93.5%) 47 (94.0%) 76 (96.2%) 186 (94.4%) 397 (94.5%)  
 Positive 6 (6.4%) 3 (6.0%) 3 (3.8%) 11 (5.6%) 23 (5.5%)  
Marital status       0.31
 Unmarried 9 (9.6%) 2 (4.0%) 3 (3.8%) 10 (5.1%) 24 (5.7%)  
 Married 85 (90.4%) 48 (96.0%) 76 (96.2%) 187 (94.9%) 396 (94.3%)  
Employment       0.84
 Employed 65 (69.1%) 37 (74.0%) 51 (64.6%) 130 (66.0%) 283 (67.4%)  
 Unemployed 13 (13.8%) 4 (8.0%) 9 (11.4%) 25 (12.7%) 51 (12.1%)  
 Retired 16 (17.0%) 9 (18.0%) 19 (24.1%) 42 (21.3%) 86 (20.5%)  
Tumor size (cm)       0.40
 0–1.9 33 (35.1%) 18 (36.0%) 33 (41.8%) 87 (44.2%) 171 (40.7%)  
 2–4.9 54 (57.4%) 30 (60.0%) 41 (51.9%) 105 (53.3%) 230 (54.8%)  
  > 5 7 (7.4%) 2 (4.0%) 5 (6.3%) 5 (2.5%) 19 (4.5%)  
Positive axillary nodal status       0.80
 0 47 (50.0%) 26 (52.0%) 46 (58.2%) 112 (56.9%) 231 (55.0%)  
 1–3 29 (30.9%) 18 (36.0%) 20 (25.3%) 61 (31.0%) 128 (30.5%)  
 4–9 12 (12.8%) 4 (8.0%) 7 (8.9%) 16 (8.1%) 39 (9.3%)  
  > 10 6 (6.4%) 2 (4.0%) 6 (7.6%) 8 (4.1%) 22 (5.2%)  
TNM stage       0.86
 Stage 0-I 31 (33.0%) 19 (38.0%) 30 (38.0%) 74 (37.6%) 154 (36.7%)  
 Stage II 46 (48.9%) 23 (46.0%) 35 (44.3%) 98 (49.7%) 202 (48.1%)  
 Stage III 17 (18.1%) 8 (16.0%) 14 (17.7%) 25 (12.7%) 64 (15.2%)  
Histological subtype       0.65
 Tubular/Mucinous/Papillary 1 (1.1%) 3 (6.0%) 2 (2.5%) 8 (4.1%) 14 (3.3%)  
 Ductal/Lobular/Mixed/Metaplastic 90 (95.7%) 46 (92.0%) 76 (96.2%) 186 (94.4%) 398 (94.8%)  
 Ductal carcinoma in situ 3 (3.2%) 1 (2.0%) 1 (1.3%) 3 (1.5%) 8 (1.9%)  
ER status       0.16
 Negative 25 (26.6%) 21 (42.0%) 19 (24.1%) 64 (32.5%) 129 (30.7%)  
 Positive 69 (73.4%) 29 (58.0%) 57 (72.2%) 132 (67.0%) 287 (68.3%)  
 Missing 0 (0.0%) 0 (0.0%) 3 (3.8%) 1 (0.5%) 4 (1.0%)  
PR status       0.28
 Negative 31 (33.0%) 24 (48.0%) 25 (31.6%) 73 (37.1%) 153 (36.4%)  
 Positive 63 (67.0%) 26 (52.0%) 51 (64.6%) 123 (62.4%) 263 (62.6%)  
 Missing 0 (0.0%) 0 (0.0%) 3 (3.8%) 1 (0.5%) 4 (1.0%)  
HER2 status       0.41
 Negative 77 (81.9%) 38 (76.0%) 65 (82.3%) 152 (77.2%) 332 (79.0%)  
 Positive 17 (18.1%) 12 (24.0%) 11 (13.9%) 44 (22.3%) 84 (20.0%)  
 Missing 0 (0.0%) 0 (0.0%) 3 (3.8%) 1 (0.5%) 4 (1.0%)  
Breast surgery       0.24
 Lumpectomy 38 (40.4%) 20 (40.0%) 35 (44.3%) 101 (51.3%) 194 (46.2%)  
 Mastectomy 56 (59.6%) 29 (58.0%) 44 (55.7%) 95 (48.2%) 224 (53.3%)  
 Missing 0 (0.0%) 1 (2.0%) 0 (0.0%) 1 (0.5%) 2 (0.5%)  
Axillary surgery       0.03
 Sentinel lymph node biopsy 37 (39.4%) 24 (48.0%) 40 (50.6%) 108 (54.8%) 209 (49.8%)  
 Axillary lymph node dissection 50 (53.2%) 24 (48.0%) 36 (45.6%) 88 (44.7%) 198 (47.1%)  
 Missing 7 (7.4%) 2 (4.0%) 3 (3.8%) 1 (0.5%) 13 (3.1%)  
Chemotherapy       < 0.01
 No 47 (50.0%) 12 (24.0%) 12 (15.2%) 28 (14.2%) 99 (23.6%)  
 Yes 47 (50.0%) 38 (76.0%) 67 (84.8%) 169 (85.8%) 321 (76.4%)  
Radiotherapy       < 0.01
 No 62 (66.0%) 23 (46.0%) 25 (31.6%) 39 (19.8%) 149 (35.5%)  
 Yes 32 (34.0%) 27 (54.0%) 54 (68.4%) 158 (80.2%) 271 (64.5%)  
Targeted therapy       0.03
 No 90 (95.7%) 45 (90.0%) 73 (92.4%) 167 (84.8%) 375 (89.3%)  
 Yes 4 (4.3%) 5 (10.0%) 6 (7.6%) 30 (15.2%) 45 (10.7%)  
Endocrine therapy       < 0.01
 No 40 (42.6%) 24 (48.0%) 17 (21.5%) 60 (30.5%) 141 (33.6%)  
 Yes 54 (57.4%) 26 (52.0%) 62 (78.5%) 137 (69.5%) 279 (66.4%)  
  1. Abbreviations: ER Estrogen receptor status, PR Progesterone receptor status, HER 2 Human epidermal growth factor receptor 2
  2. *p from chi-square test or Fisher’s exact test based on complete cases
\